After the MedTech giant Stryker (NYSE:SYK) agreed to offer $4.9B in cash to acquire Inari Medical (NASDAQ:NARI), a maker of ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $270.00. The ...

US-based Penumbra has completed enrolment for the THUNDER Investigational Device Exemption study of its advanced thrombectomy ...

In May of last year, I concluded that appeal was improving in the case of Penumbra (NYSE:PEN), with operating leverage being demonstrated upon. The neurovascular player was finally enjoying some ...

[113] The Penumbra System is the other mechanical recanalization device that has been approved by the FDA. It employs both grasping and aspiration mechanisms for clot retrieval. [114] In January ...

THUNDER is evaluating the safety and efficacy of the company's latest computer assisted vacuum thrombectomy (CAVT™) technology, Penumbra System™ with Thunderbolt™ Aspiration Tubing ...

In a report released on January 6, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Penumbra (PEN – Research Report), with a ...

Our proprietary system currently recommends Penumbra (PEN) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Studies have shown that stocks ...

In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter ...

After the MedTech giant Stryker (NYSE:SYK) agreed to offer $4.9B in cash to acquire Inari Medical (NASDAQ:NARI), a maker of clot removal systems, shares of its rival Penumbra (NYSE:PEN ...